Yu-Wen Li

发表

Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats

W. Hayes, R. Pieschl, L. Bristow, 2018, Journal of psychopharmacology.

Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus

Laszlo Kiss, R. Pieschl, J. Graef, 2015, Brain Research.

40 Hz Auditory Steady-State Response Is a Pharmacodynamic Biomarker for Cortical NMDA Receptors

M. Ahlijanian, Yulia Benitex, Yili Yang, 2016, Neuropsychopharmacology.

Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, (±)-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for Corticotropin-Releasing Factor1 Receptors

D. Rominger, C. Rominger, Xiao-Xin Yan, 2003, Journal of Pharmacology and Experimental Therapeutics.

Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.

R. Pieschl, K. Rohrbach, N. Lodge, 2014, European journal of pharmacology.

In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Vijay T. Ahuja, J. Macor, H. Wong, 2009, Journal of medicinal chemistry.

Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.

Yu-Wen Li, P. Gilligan, 2004, Current opinion in drug discovery & development.

Bacillus Calmette–Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice

L. Bristow, J. Louis, Rajbharan Yadav, 2014, Brain, Behavior, and Immunity.

Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P1 Receptor Modulator.

Michael G. Yang, K. McIntyre, D. Shen, 2016, Journal of medicinal chemistry.

Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.

R. Pieschl, L. Bristow, A. Fernandes, 2015, European journal of pharmacology.

Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.

C. Albright, R. Olson, J. Toyn, 2007, The Journal of pharmacology and experimental therapeutics.

Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy

G. Trainor, R. Taub, H. Wong, 2003, Journal of Pharmacology and Experimental Therapeutics.

Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain

A. Fernandes, Yu-Wen Li, 2017, Brain Research.

Receptor Occupancy of Non-Peptide CRF 1 Antagonist DMP 696 : Correlation with Drug Exposure and Anxiolytic Efficacy

G. Trainor, R. Taub, S. Grossman, 2002 .

A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Vijay T. Ahuja, J. Macor, Y. Shu, 2009, Journal of medicinal chemistry.

The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.

H. Wong, M. D. Lindner, N. Lodge, 2006, CNS drug reviews.

5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists.

J. Macor, T. Molski, R. Olson, 2010, Bioorganic & medicinal chemistry letters.

Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

J. Macor, Shuang Liu, T. Molski, 2014, ACS medicinal chemistry letters.

Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5.

J. Macor, Amy Easton, Anand Balakrishnan, 2016, ACS medicinal chemistry letters.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Binding Sites of γ-Secretase Inhibitors in Rodent Brain: Distribution, Postnatal Development, and Effect of Deafferentation

P. Wong, R. Olson, C. Rominger, 2004, The Journal of Neuroscience.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor1 (CRF1) Antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004, Journal of Pharmacology and Experimental Therapeutics.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor 1 ( CRF 1 ) Antagonist DMP 904 [ 4-( 3-pentylamino )-2 , 7-dimethyl-8-( 2-methyl-4-methoxyphenyl )-pyrazolo-[ 1 , 5-a ]-pyrimidine ] Administered Acutely or Chronically at Doses Occupying Central CRF 1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004 .

Anxiolytic-like Effects of the CRF1 Antagonist DMP904 Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, R. Taub, H. Wong, 2003 .

Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy

M. Seager, J. Macor, S. Gerritz, 2016, Neuropharmacology.

Synergistic antinociception of propofol–alfentanil combination in mice

Jingwen Wang, Chao Wang, Yu-Wen Li, 2014, Pharmacology Biochemistry and Behavior.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.

S. Arneric, G. Trainor, H. Wong, 2009, Journal of medicinal chemistry.

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia

J. Macor, Yulia Benitex, D. Post‐Munson, 2016, PloS one.

Effects of BMS‐902483, an &agr;7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents

Y. Asaka, J. Macor, J. Herrington, 2017, European journal of pharmacology.

Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.

G. Shankar, J. Macor, C. Albright, 2022, Journal of medicinal chemistry.

Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus

B. Srikumar, R. Pieschl, L. Bristow, 2018, Journal of psychopharmacology.

Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.

Alan G. E. Wilson, G. Shankar, J. Macor, 2022, Journal of medicinal chemistry.

NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test

J. Macor, R. Pieschl, T. Molski, 2013, Neuropharmacology.

Ion channels as potential targets for the treatment of depression.

N. Lodge, Yu-Wen Li, 2008, Current opinion in drug discovery & development.

8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.

Lawrence Fitzgerald, Ge Zhang, Harvey Wong, 2009, Journal of medicinal chemistry.

6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats

R. Taub, H. Wong, R. Dockens, 2007, Drug Metabolism and Disposition.

Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534

J. Macor, D. Post‐Munson, T. Molski, 2013, Neuropharmacology.

Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment

B. Srikumar, R. Pieschl, L. Bristow, 2017, Pharmacology Biochemistry and Behavior.

Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance

R. Pieschl, T. Molski, N. Lodge, 2008, Neuropharmacology.

Ex Vivo Occupancy of γ-Secretase Inhibitors Correlates with Brain β-Amyloid Peptide Reduction in Tg2576 Mice

C. Albright, R. Olson, J. Toyn, 2007, Journal of Pharmacology and Experimental Therapeutics.

NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats

M. Ahlijanian, R. Pieschl, Yili Yang, 2014, Front. Psychiatry.

Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors.

M. Imaizumi, S. Zoghbi, V. Pike, 2014, Nuclear medicine and biology.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

[3H]BMT-046091 a potent and selective radioligand to determine AAK1 distribution and target engagement

J. Macor, C. Albright, R. Pieschl, 2017, Neuropharmacology.

Inhibition of AAK 1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain s

Alan G. E. Wilson, Malley, G. Shankar, 2016 .

[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.

Vijay T. Ahuja, J. Macor, T. Molski, 2012, Bioorganic & medicinal chemistry letters.

Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Joseph Payne, Vijay T. Ahuja, Yue-Zhong Shu, 2009, Journal of medicinal chemistry.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder

J. Macor, A. Mathur, B. Srikumar, 2017, The Journal of Pharmacology and Experimental Therapeutics.